Physician profile
John K Kim
NPI 1053472159
$9,370.78
in general payments reported to CMS, 2019-2025
54 companies · $1,331 in 2025
The $1,331 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $1,188 · 2021: $1,702 · 2022: $1,243 · 2023: $1,579 · 2024: $1,745 · 2025: $1,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,459 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,459.47 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $849.11 | 2019-2025 | |
| Novo Nordisk INC | $724.91 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $618.05 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $593.65 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Scilex Pharmaceuticals INC. | $513.43 | 2020-2025 | Ztlido |
| Glaxosmithkline, LLC. | $473.07 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $468.96 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $413.92 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $406.89 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $355.48 | 2022-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $346.36 | 2024-2025 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $331.39 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.98 | 2020-2025 | Jardiance |
| Horizon Therapeutics Plc | $231.54 | 2022-2023 | Krystexxa |
| Allergan, INC. | $213.54 | 2019-2020 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.